Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and biologic drug candidates for cancer and autoimmune diseases. The company operates within the biotechnology and life sciences industry, with an emphasis on immune-based therapies designed to modulate or harness the body’s immune system to treat complex and life‑threatening conditions.
Immix Biopharma’s primary value driver is its pipeline of proprietary drug candidates, particularly its lead program targeting solid tumors and inflammatory diseases using immune-modulating mechanisms. The company’s strategic positioning centers on advancing differentiated therapies through early- and mid-stage clinical development rather than commercial-stage product sales. Immix Biopharma was founded in 2012 and evolved from a privately held research-focused entity into a publicly traded company following its initial public offering in 2021, providing capital to advance its clinical pipeline.
Business Operations
Immix Biopharma’s operations are organized around research and development activities rather than commercial manufacturing or sales. Its core business units focus on drug discovery, preclinical research, clinical trial execution, regulatory strategy, and intellectual property management. Revenue generation is limited, as the company does not currently market approved products; operating capital is primarily derived from equity financing and, to a lesser extent, grants or collaboration-related funding when applicable.
The company’s lead therapeutic programs include IMX‑110, a tissue-selective immune effector designed for solid tumors, and IMX‑120, which targets inflammatory and autoimmune conditions. Immix Biopharma conducts clinical trials in collaboration with third-party contract research organizations and clinical sites, while maintaining internal oversight of trial design and regulatory compliance. The company does not publicly disclose large-scale manufacturing assets and instead relies on external partners for clinical-grade production.
Strategic Position & Investments
Immix Biopharma’s strategic direction is centered on advancing its lead clinical assets through defined clinical milestones to increase enterprise value and potential partnering opportunities. Growth initiatives are primarily focused on expanding clinical data for IMX‑110 and IMX‑120 and exploring additional indications where immune modulation may provide therapeutic benefit. The company emphasizes capital efficiency and targeted clinical development rather than broad portfolio expansion.
There is no verified public disclosure of major acquisitions or large equity investments in other companies. Immix Biopharma’s strategy relies on organic development of internally discovered assets rather than acquisitive growth. Data inconclusive based on available public sources regarding any undisclosed joint ventures or material minority investments beyond routine research collaborations.
Geographic Footprint
Immix Biopharma is headquartered in the United States, with its principal executive offices located in California. Its operational footprint is primarily domestic, centered on corporate management, research oversight, and regulatory coordination within the U.S. biotechnology ecosystem.
International presence is largely indirect and occurs through global clinical trial sites and third-party vendors supporting studies outside the U.S., including in Europe and other regions when required by trial protocols. The company does not report significant international subsidiaries or standalone foreign operating entities based on publicly available filings.
Leadership & Governance
Immix Biopharma is led by a management team with experience in biotechnology research, clinical development, and public company operations. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and milestone-driven development aligned with regulatory standards.
Key executives include:
- Ilya Rachman – Chief Executive Officer and Chairman of the Board
- William T. Schuette – Chief Financial Officer
- Dr. Joseph Scheerer – Chief Scientific Officer
- Dr. Steven King – Head of Clinical Development
The board of directors provides governance oversight with a focus on clinical progress, financial stewardship, and shareholder interests, consistent with requirements outlined in SEC filings.